Πίσω από την εβραϊκών συμφερόντων PFIZER, Ο ΚΑΜΠΑΛΙΣΤΗΣ ΜΠΙΛ ΓΚΕΙΤΣ.

Πίσω από την εβραϊκών συμφερόντων PFIZER, Ο ΚΑΜΠΑΛΙΣΤΗΣ ΜΠΙΛ ΓΚΕΙΤΣ.

12 Νοεμβρίου, 2020 3 Από Καλλιόπη Σουφλή
Προβολές:592
Μοίρασέ το

Coronavirus: Ο Bill Gates δίνει το Pfizer εμβόλιο για έγκριση στις ΗΠΑ

 

Όποια πέτρα και να σηκώσεις στην φαρμακοβιομηχανία, από κάτω θα βρεις τον ΚΑΜΠΑΛΙΣΤΗ ΕΒΡΑΙΟ ΜΠΙΛ ΓΚΕΙΤΣ.

ΤΟΝ ΕΒΡΑΙΟ ΠΟΥ ΣΤΟΧΕΥΕΙ ΣΤΗΝ ΜΕΙΩΣΗ ΤΗΣ ΑΝΘΡΩΠΟΤΗΤΑΣ ΚΑΙ ΕΥΘΥΝΕΤΑΙ ΓΙΑ ΕΚΑΤΟΜΜΥΡΙΑ ΘΑΝΑΤΟΥΣ ΣΤΗΝ ΑΦΡΙΚΗ ΚΑΙ ΣΤΗΝ ΑΣΙΑ ΑΠΟ ΤΑ ΤΟΞΙΚΑ ΤΟΥ ΕΜΒΟΛΙΑ.

Είναι δυνατόν να το αγνοούν οι φαρμακευτικές εταιρείες και οι… διευθύνοντες σύμβουλοί τους;

ΑΠΟΚΛΕΙΕΤΑΙ…. αφού πολλοί απ’ αυτούς είναι εβραϊκής καταγωγής… και ο νοών, νοείτο …

ΠΟΙΟΣ ΤΟΥΣ ΕΧΡΗΣΕ “ΘΕΟΥΣ” ΚΑΙ ΕΞΟΥΣΙΑΣΤΕΣ ΤΗΣ ΑΝΘΡΩΠΙΝΗΣ ΖΩΗΣ;;;

 

Καλλιόπη Σουφλή

 

“Το μόνο εμβόλιο που, αν όλα πάνε καλά, θα μπορούσε να εγκριθεί μέχρι τα τέλη Οκτωβρίου θα ήταν το Pfizer”, δήλωσε ο Γκέιτς.

 

Bill Gates doesn’t expect a virus vaccine before year-end — but he says one drugmaker has the best chance

  • “None of the vaccines are likely to seek approval in the U.S. before the end of October,” the billionaire philanthropist told CNBC via video conference. 
  • “The only vaccine that if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer,” Gates said.
  • Over the weekend, Pfizer made a request to the FDA to expand the late-stage trial to include up to 44,000 participants, up from its earlier target of 30,000.
Bill Gates addresses a virtual Covid-19 conference hosted by the International Aids Society. July 11, 2020
Bill Gates addresses a virtual Covid-19 conference hosted by the International Aids Society. July 11, 2020
International Aids Society Handout

Bill Gates doesn’t believe any of the coronavirus vaccines in development are likely to seek U.S. approval before the end of October something that would be bad news for President Donald Trump, who has hinted at a viable vaccine to counter the pandemic before the Nov. 3 election. 

“None of the vaccines are likely to seek approval in the U.S. before the end of October,” the billionaire philanthropist told CNBC via video conference last week. 

 

But Gates is more confident about a breakthrough by early next year and named one drugmaker as being the furthest ahead.

“I do think once you get into, say, December or January, the chances are that at least two or three will (seek approval) if the effectiveness is there,” the Microsoft co-founder said.

“And so we have these phase three trials that are going on. The only vaccine that if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer.

The Gates Foundation, created by Gates and his wife, Melinda, announced in March a collaboration to develop a coronavirus vaccine with several life sciences companies including Pfizer. It also owns stock in Pfizer, as well as Johnson & Johnson, Merck and others and has given multimillion-dollar grants to Pfizer for the development of various vaccines in recent years.

Pfizer CEO on a breakthrough

On Monday, Pfizer CEO Albert Bourla told CNBC that its coronavirus vaccine, one of three vaccines from the West in late-stage testing, could be distributed to Americans before the end of the year if found to be safe and effective. The other drugmakers in late-stage testing that will potentially seek U.S. approval are Moderna and U.K.-based AstraZeneca.

 

“We do see good antibody levels both in the phase one and the phase two, so we’re pretty hopeful,” Gates said of those trials.

 
 
Watch CNBC’s full interview with Pfizer CEO Albert Bourla
 
 

 

Beyond the U.S. and Europe, Russia and China have approved emergency use of their own vaccines, although these have been met with skepticism from some Western medical professionals.

If approved by the Food and Drug Administration, Pfizer is prepared to distribute “hundreds of thousands of doses,” Bourla said, adding that the company should have late-stage trial data by the end of October. He said Pfizer had already invested $1.5 billion for the potential vaccine’s development.

Over the weekend, Pfizer made a request to the FDA to expand the late-stage trial to include up to 44,000 participants, up from its earlier target of 30,000.

The American pharmaceutical giant has been working with German drug company BioNTech, and the U.S. government in July announced it would pay the firms $1.95 billion to produce and deliver 100 million doses of their vaccine if it proves safe and effective.

VIDEO01:45
Could Covid-19 antiviral therapeutics be more important than a vaccine?
 

 

The deal was signed as part of Operation Warp Speed, the Trump administration’s effort to accelerate development and production of vaccines and treatments to fight the coronavirus.

Concerns over political pressure

The Centers for Disease Control and Prevention have told U.S. states to be ready for vaccine distribution as early as Nov. 1, in line with Trump’s reported push for a vaccine before the election. But the timing has caused concern among some experts who fear that safety protocols will be sidestepped for political reasons. 

For Gates, a pledge from leading vaccine developers gives him confidence that that won’t happen. 

“The good news is that the leading vaccine companies today said that they won’t apply even for the emergency use license until they have a proof of efficacy,” he told CNBC. “We also have to go through all the safety steps so that people feel like they want to participate in taking this vaccine.”

In a rare public letter published Sept. 8, the chief executives of nine major drugmakers pledged not to seek approval for their vaccines until their safety and effectiveness was proven in large clinical trials. The letter came amid reports that Trump was attempting to bypass the FDA’s standard approvals process to get fast-track emergency use approval for an experimental vaccine, even if it hasn’t yet received full regulatory approval. CNBC has reached out to the White House for comment.

“In the interest of public health, we pledge to always make the safety and well-being of vaccinated individuals our top priority,” the letter said. It was signed by the CEOs of Pfizer, AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Moderna, Novavax and Sanofi.

 

Πηγή

Προβολές : 592


Μοίρασέ το:



Ετικέτες: , , ,

ΕΠΙΣΗΜΑΝΣΗ


Ορισμένα αναρτώμενα από το διαδίκτυο κείμενα ή εικόνες, θεωρούμε ότι είναι δημόσια. Αν υπάρχουν δικαιώματα συγγραφέων, παρακαλούμε ενημερώστε μας, για να τα αφαιρέσουμε. Επίσης, σημειώνεται ότι οι απόψεις του ιστολογίου, μπορεί να μην συμπίπτουν με τα περιεχόμενα του άρθρου. Για τα άρθρα που δημοσιεύονται εδώ, ουδεμία ευθύνη εκ του νόμου φέρουμε, καθώς απηχούν αποκλειστικά τις απόψεις των συντακτών τους και δεν δεσμεύουν καθ’ οιοδνήποτε τρόπο, το ιστολόγιο. Ο διαχειριστής του ιστολογίου, δεν ευθύνεται για τα σχόλια και τους δεσμούς που περιλαμβάνει. Τονίζουμε ότι υφίσταται μετριασμός των σχολίων και παρακαλούμε, πριν δημοσιεύσετε το σχόλιό σας, να έχετε υπόψη σας τα ακόλουθα:
  • Κάθε γνώμη είναι σεβαστή, αρκεί να αποφεύγονται ύβρεις, ειρωνείες, ασυνάρτητος λόγος και προσβλητικοί χαρακτηρισμοί, πολύ περισσότερο σε προσωπικό επίπεδο, εναντίον των συνομιλητών ή και των συγγραφέων, με υποτιμητικές προσφωνήσεις, ύβρεις, υπονοούμενα, απειλές ή χυδαιολογίες.>
  • Μην δημοσιεύετε άσχετα με το θέμα σχόλια.
  • Ο κάθε σχολιαστής, οφείλει να διατηρεί ένα μόνον όνομα ή ψευδώνυμο, το οποίο αποτελεί και την ταυτότητά του σε κάθε συζήτηση.
  • Με βάση τα παραπάνω, η διαχείριση, διατηρεί το δικαίωμα μη δημοσίευσης σχολίων, χωρίς καμία άλλη προειδοποίηση.
  • Επιπλέον σας τονίζουμε, ότι το ιστολόγιο, λειτουργεί σε εθελοντική βάση και ως εκ τούτου, τα σχόλια θα αναρτώνται μόλις αυτό καταστεί δυνατόν.

Διαβάστε ακόμα